Loading quotes...
Forecast
The analysts' average price target is €13.65 (+245.57%). The median is €13.65 (+245.57%).
| Buy |
Â
11 |
| Hold |
Â
4 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Precigen reaches 52-week high at $7.33 after strong quarter
Precigen's stock rose to a 52-week high of $7.33 and has a market capitalization of about $2.62 billion. Over the past year the share price has more than doubled (+100.27%); InvestingPro reports a total return of 123% and a YTD gain of 71%. In the second quarter the company beat expectations with earnings of $0.05 per share (expectation: -$0.01) and revenue of $54.98 million (forecast: $27.83 million), driven by strong demand for PAPZIMEOS; net income was $20.1 million. » More on de.investing.com
Precigen beats Q2 forecasts thanks to strong PAPZIMEOS demand
Precigen reported Q2 net income of $20.1 million ($0.05 per share) on revenue of $54.98 million, well above consensus estimates of -$0.01 EPS and $27.83 million in revenue. PAPZIMEOS generated $53.1 million, or 96.4% of revenue; more than 200 patients have received at least one dose and over 100 have completed the full four‑injection treatment. The stock rose 12.56% in after‑hours trading to $7.35 and surpassed its 52‑week high. Management expects continued growth, margin stabilization in the high 80s to low 90s percent range, and cash‑flow breakeven by the end of 2026, but warns of revenue concentration in a single product and existing debt of $100 million. » More on de.investing.com
Precigen secures U.S. market exclusivity for PAPZIMEOS until 2032
Precigen holds the first and only FDA-approved therapy for the treatment of recurrent respiratory papillomatosis (RRP) in adults with PAPZIMEOS and has U.S. market exclusivity until 2032. Peak sales potential is over $1 billion, and H.C. Wainwright forecasts more than a doubling of the share price. PAPZIMEOS revenues rose sequentially by more than 535 percent, with growth expected to accelerate further in Q2. The 2028e P/E is stated at 7.4. » More on finanzen.net
Precigen secures FDA orphan drug exclusivity for PAPZIMEOS
Precigen won FDA orphan drug exclusivity for PAPZIMEOS, granting seven years of protection that extends market exclusivity through August 2032. PAPZIMEOS, developed with the AdenoVerse platform, targets HPV 6 and 11 to treat adult recurrent respiratory papillomatosis (RRP) and is commercially available in the US. Long-term data presented at ASCO 2026 showed sustained benefit: 83% of complete responders remained surgery-free for at least 36 months and some patients required no interventions beyond four years. » More on finance.yahoo.com
Precigen beats Q1 2026 forecasts, stock rises after strong PAPZIMEOS sales
Precigen reported Q1 2026 EPS of $-0.02 (forecast -$0.03) and revenue of $23.25 million, driven by the commercial success of PAPZIMEOS. Operating results improved and the stock rose 10.84% in after-hours trading. Management expects continued revenue growth, reduced cash burn and targets cash‑flow break‑even by the end of 2026, but sees risks from high SG&A costs and dependence on PAPZIMEOS. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 65.46M | 2,529.06% |
| Gross profit | 59.72M | 4,366.44% |
| Net profit | 31.58M | 125.32% |
| EBITDA | 35.38M | 128.70% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.4B |
Number of shares | 358.55M |
52-week high/low | €8.17 - €2.77 |
| Dividends | No |
Beta | 0.98 |
P/E ratio | 62.81 |
PEG ratio | 0.40 |
P/B ratio | 18.34 |
P/S ratio | 9.80 |
Company profile
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
| Name | Precigen |
| CEO | Helen Sabzevari |
| Headquarters | Germantown,
md USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 08/08/2013 |
| Employees | 160 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | PGEN |
Frankfurt | I5X.F |
DĂĽsseldorf | I5X.DU |
SIX | I5X.SW |
MĂĽnchen | I5X.MU |